Who
Christina Shafer
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Neurogene; Chief Commercial Officer, Marinus Pharmaceuticals.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $48K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 9 Nov 2022
- Last trade
- 5 May 2026
- Last filed
- 7 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 May 2026filed 7 May 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —49,125 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —98,250 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —78,188 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —57,900 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —128,000 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticals | SEC FORM 4 Code D | $27K48,628 at $0.55 | filing |
| 7 Feb 2025filed 11 Feb 2025 | Marinus Pharmaceuticals | SEC FORM 4 Code D | $10K18,778 at $0.55 | filing |
| 5 Aug 2024filed 7 Aug 2024 | Marinus Pharmaceuticals | SEC FORM 4 Sold | $4,3553,820 at $1.14 | filing |
| 18 Jun 2024filed 20 Jun 2024 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —49,125 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | Marinus Pharmaceuticals | SEC FORM 4 Code A | —10,918 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | Marinus Pharmaceuticals | SEC FORM 4 Sold | $21K2,153 at $9.56 | filing |
| 18 Jan 2024filed 19 Jan 2024 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —98,250 at $0.00 | filing |
| 18 Jan 2024filed 19 Jan 2024 | Marinus Pharmaceuticals | SEC FORM 4 Code A | —21,835 at $0.00 | filing |
| 8 Aug 2023filed 8 Aug 2023 | Marinus Pharmaceuticals | SEC FORM 4 Sold | $9811 at $8.93 | filing |
| 7 Aug 2023filed 8 Aug 2023 | Marinus Pharmaceuticals | SEC FORM 4 Sold | $23K2,385 at $9.52 | filing |
| 26 Jan 2023filed 30 Jan 2023 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —78,188 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | Marinus Pharmaceuticals | SEC FORM 4 Code A | —17,375 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.